114 related articles for article (PubMed ID: 11800646)
1. Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2002 Jan; 126(1):42-8. PubMed ID: 11800646
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome.
Korshunov A; Shishkina L; Golanov A
Int J Cancer; 2003 May; 104(6):728-34. PubMed ID: 12640680
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
6. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
Deininger MH; Weller M; Streffer J; Meyermann R
Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
Park SH; Suh YL
Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans.
Fiano V; Ghimenti C; Schiffer D
Neurosci Lett; 2003 Aug; 347(2):111-5. PubMed ID: 12873740
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.
Miettinen HE; Paunu N; Rantala I; Kalimo H; Paljärvi L; Helin H; Haapasalo H
J Neurooncol; 2001 Oct; 55(1):29-37. PubMed ID: 11804280
[TBL] [Abstract][Full Text] [Related]
10. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
Korshunov A; Golanov A; Timirgaz V
Acta Neuropathol; 2001 Sep; 102(3):271-7. PubMed ID: 11585252
[TBL] [Abstract][Full Text] [Related]
11. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
Reis-Filho JS; Faoro LN; Carrilho C; Bleggi-Torres LF; Schmitt FC
Cancer; 2000 Feb; 88(4):862-9. PubMed ID: 10679656
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
Majumdar K; Radotra BD; Vasishta RK; Pathak A
Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
[TBL] [Abstract][Full Text] [Related]
14. p53 immunoreactivity in oligodendrogliomas.
Pavelić J; Hlavka V; Poljak M; Gale N; Pavelić K
J Neurooncol; 1994; 22(1):1-6. PubMed ID: 7714546
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival.
Varlet P; Guillamo JS; Nataf F; Koziak M; Beuvon F; Daumas-Duport C
Neuropathol Appl Neurobiol; 2000 Aug; 26(4):379-89. PubMed ID: 10931372
[TBL] [Abstract][Full Text] [Related]
16. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
[TBL] [Abstract][Full Text] [Related]
18. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.
Watanabe T; Nakamura M; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2001 Mar; 101(3):185-9. PubMed ID: 11307615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
